N-(2-氯乙基)-N'-(4-氟苯基)脲 | 13908-32-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-(2-氯乙基)-N'-(4-氟苯基)脲
• 英文名称: 1-(2-chloroethyl)-3-(4-fluorophenyl)urea
• 英文别名: N-(2-chloroethyl)-N'-(4-fluorophenyl)urea
• CAS: 13908-32-2
• 化学式: C₉H₁₀ClFN₂O
• mdl: MFCD03787786
• 分子量: 216.643
• InChiKey: NQVQWNNGRKPRIW-UHFFFAOYSA-N

物化性质

• 熔点：
  132°C
• 沸点：
  295.7±40.0 °C(Predicted)
• 密度：
  1.325±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  41.1
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 海关编码：
  2924299090

反应信息

• 作为反应物：
  描述：

  N-(2-氯乙基)-N'-(4-氟苯基)脲 在 哌啶 、 N-羟基-7-氮杂苯并三氮唑 、 lithium hydroxide monohydrate 、 水 、 sodium hydride 、 potassium carbonate 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 四氢呋喃 、 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 33.67h， 生成 N-[(1S)-5-amino-1-cyano-pentyl]-6-[[3-(4-fluorophenyl)-2-oxo-imidazolidin-1-yl]methyl]-7-methyl-pyrrolo[2,3-d]pyrimidine-2-carboxamide
  参考文献：
  名称：

  Pyrrolopyrimidine-inhibitors with hydantoin moiety as spacer can explore P4/S4 interaction on plasmin

  摘要：

  In the development of plasmin inhibitors, a novel chemotype, pyrrolopyrimidine scaffold possessing two motifs, a hydantoin-containing P4 moiety and a warhead-containing P1 moiety, is uncovered. A unique feature of the new line of the plasmin inhibitors is that the interaction between the plasmin inhibitors and key subsites in plasmin can be controlled by a spacer like hydantoin. The application of the novel chemotype is demonstrated by 1n and provides further evidence on the importance of hydantoin as the spacer. (c) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2014.02.002
• 作为产物：
  描述：

  氯乙基异氰酸酯 、 4-氟苯胺 以 二氯甲烷 为溶剂， 反应 15.0h， 以96%的产率得到N-(2-氯乙基)-N'-(4-氟苯基)脲
  参考文献：
  名称：

  Pyrrolopyrimidine-inhibitors with hydantoin moiety as spacer can explore P4/S4 interaction on plasmin

  摘要：

  In the development of plasmin inhibitors, a novel chemotype, pyrrolopyrimidine scaffold possessing two motifs, a hydantoin-containing P4 moiety and a warhead-containing P1 moiety, is uncovered. A unique feature of the new line of the plasmin inhibitors is that the interaction between the plasmin inhibitors and key subsites in plasmin can be controlled by a spacer like hydantoin. The application of the novel chemotype is demonstrated by 1n and provides further evidence on the importance of hydantoin as the spacer. (c) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2014.02.002

文献信息

• [EN] 2,4-SUBSTITUTED PYRIMIDINES AS CYSTEINE PROTEASE INHIBITORS<br/>[FR] PYRIMIDINES 2,4-SUBSTITUEES SERVANT D'INHIBITEURS DE CYSTEINE PROTEASE
  申请人：GLAXO GROUP LTD

  公开号：WO2006027211A1

  公开（公告）日：2006-03-16

  Substituted heteroaryl nitrile derivatives of Formula (I) processes for their preparation, pharmaceutical compositions comprising such compounds and use of the compounds as cysteine protease inhibitors are provided.

  提供了公式（I）的取代杂环亚硝基腈衍生物的制备方法，包括这些化合物的制药组合物以及将这些化合物用作半胱氨酸蛋白酶抑制剂的用途。
• New Substituted 1-(2,3-Dihydrobenzo[1,4]dioxin-2-ylmethyl)piperidin-4-yl Derivatives with α₂-Adrenoceptor Antagonist Activity
  作者：Patrice Mayer、Pascale Brunel、Céline Chaplain、Christel Piedecoq、Francis Calmel、Philippe Schambel、Philippe Chopin、Thierry Wurch、Petrus J. Pauwels、Marc Marien、Jean-Louis Vidaluc、Thierry Imbert

  DOI：10.1021/jm991121g

  日期：2000.10.1

  The emergence of a novel theory concerning the role of noradrenaline in the progression and the treatment of neurodegenerative diseases such as Parkinson's and Alzheimer's diseases has provided a new impetus toward the discovery of novel compounds acting at alpha(2)-adrenoceptors. A series of substituted 1-(2,3-dihydrobenzo[1,4]dioxin-2-ylmethyl) piperidin-4-yl derivatives bearing an amide, urea, or imidazolidinone moiety was studied. Some members of this series of compounds proved to be potent alpha(2)-adrenoceptor antagonists with good selectivity versus alpha(1)-adrenergic and D(2)-dopamine receptors. Particular emphasis is given to compound 33g which displays potent alpha(2)-adrenoceptor binding affinity in vitro and central effects in vivo following oral administration.
• The Synthesis of Potential Anticancer Agents. XXXVI. N-Nitrosoureas.¹ II. Haloalkyl Derivatives
  作者：Thomas P. Johnston、George S. McCaleb、Pamela S. Opliger、John A. Montgomery

  DOI：10.1021/jm00324a026

  日期：1966.11
• [EN] NOVEL CYSTEINE PROTEASE INHIBITORS<br/>[FR] NOUVEAUX INHIBITEURS DE LA CYSTEINE PROTEASE
  申请人：GLAXO GROUP LTD

  公开号：WO2007025776A2

  公开（公告）日：2007-03-08

  [EN] Substituted heteroaryl nitrile derivatives of Formula (I), processes for their preparation, pharmaceutical compositions comprising such compounds and use of the compounds as cysteine protease inhibitors are provided.
  [FR] L'invention concerne des dérivés hétéroaryle nitrilés substitués de formule (I), des procédés de préparation de ces composés, des compositions pharmaceutiques les contenant, ainsi que leur utilisation en tant qu'inhibiteurs de la cystéine protéase.
• Pyrrolopyrimidine-inhibitors with hydantoin moiety as spacer can explore P4/S4 interaction on plasmin
  作者：Naoki Teno、Keigo Gohda、Keiko Wanaka、Yuko Tsuda、Takuya Sueda、Yukiko Yamashita、Tadamune Otsubo

  DOI：10.1016/j.bmc.2014.02.002

  日期：2014.4

  In the development of plasmin inhibitors, a novel chemotype, pyrrolopyrimidine scaffold possessing two motifs, a hydantoin-containing P4 moiety and a warhead-containing P1 moiety, is uncovered. A unique feature of the new line of the plasmin inhibitors is that the interaction between the plasmin inhibitors and key subsites in plasmin can be controlled by a spacer like hydantoin. The application of the novel chemotype is demonstrated by 1n and provides further evidence on the importance of hydantoin as the spacer. (c) 2014 Elsevier Ltd. All rights reserved.